pitrakinra pegylated formulation (AER 003) / Aerovance - LARVOL DELTA

Targeting IL-4 for the Treatment of Atopic Dermatitis. (PubMed, Immunotargets Ther) - "The dual inhibition of these two cytokines or the selective inhibition of IL-13 proved elevated efficacy in treating AD, whereas the selective inhibition of IL-4 has been poorly investigated as IL-4 inhibiting agents did not show any advance in clinical development programs. This review describes the pathogenic role of IL-4 in AD and briefly resumes the main features of compounds selectively blocking IL-4."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • IL13 • IL4

The Discovery and Development of AZD1402/PRS-060, an Inhaled, Potent and Selective Antagonist of the IL-4 Receptor Alpha (ERS 2018) - "...AZD1402/PRS-060 and dupilumab (IL-4R mAb) inhibited IL-4 and IL-13 induced proliferation of TF1 cells with similar potency (IC50 0.9 and 0.3 nM). In an Air Liquid Interface goblet cell differentiation assay induced by IL-13 stimulation, AZD1402/PRS-060 inhibited goblet cell metaplasia to a similar extent as AMG317 (IL-4R mAb) and pitrakinra...In the OVA model, inflammatory cell infiltration was reduced by 78% and TARC (CCL17) was reduced by 98% 48 h post challenge. AZD1402/PRS-060, potently inhibits IL-4 and IL-13 signalling in vitro and in vivo and based on these data and the proven benefit of targeting this receptor, AZD1402/PRS-060 has progressed into human clinical trials."

Asthma • Biosimilar • Immunology

Design and validation of a disease network of inflammatory processes in the NSG-UC mouse model. (PubMed, J Transl Med) - "The combination of the disease network and the NSG-UC animal model might be developed into a powerful tool to predict efficacy or in-efficacy and potential mechanistic side effects."

Journal • Preclinical